Why the study?
Genetic diversity of circulating strains is a major problem in developing recombinant rotavirus A vaccines as alternatives to live oral attenuated vaccines.
Five antigens representing structural proteins of different genotypes can be combined to develop a broad-spectrum recombinant rotavirus A vaccine.
Answers are grounded in this paper and cite their sources.
Advances antigen selection for recombinant rotavirus vaccines; leaves open immunogenicity and efficacy testing before clinical use.
PURPOSE: Recombinant rotavirus A vaccines are being developed as an alternative to existing live oral attenuated vaccines. One of the main problems in the production of such vaccines is the genetic diversity of the strains that are in circulation. The goal of this study was to create an antigen panel for modern broad-spectrum recombinant rotavirus A vaccine. MATERIALS AND METHODS: protein fragment of human RVA isolates representing genotypes P[4], P[6], and P[8]. RESULTS: and ep-875 antigens was confirmed. The problems of serological mismatch of vaccine strains and antigens with currently circulating strains are discussed. CONCLUSION: Five antigens representing sequences of structural proteins belonging to different genotypes can be used in various combinations (from mono- to pentavalent mixtures) for the development of an effective broad-spectrum rotavirus vaccine.
No takes yet. Share an insight, caveat, or question.
Кондакова et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: